Captrust Financial Advisors Clearside Biomedical, Inc. Transaction History
Captrust Financial Advisors
- $33 Billion
- Q3 2024
A detailed history of Captrust Financial Advisors transactions in Clearside Biomedical, Inc. stock. As of the latest transaction made, Captrust Financial Advisors holds 92,735 shares of CLSD stock, worth $93,662. This represents 0.0% of its overall portfolio holdings.
Number of Shares
92,735
Previous 87,000
6.59%
Holding current value
$93,662
Previous $113,000
3.54%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding CLSD
# of Institutions
55Shares Held
12.2MCall Options Held
54.7KPut Options Held
50.7K-
Vanguard Group Inc Valley Forge, PA2.84MShares$2.87 Million0.0% of portfolio
-
Act Capital Management, LLC Wayne, PA2.2MShares$2.22 Million3.43% of portfolio
-
Carmignac Gestion Paris, I01.93MShares$1.95 Million0.04% of portfolio
-
Black Rock Inc. New York, NY798KShares$806,1180.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny745KShares$752,3370.0% of portfolio
About Clearside Biomedical, Inc.
- Ticker CLSD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,190,700
- Market Cap $60.8M
- Description
- Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injec...